Anti-metastatic effect of Biophytum sensitivum is exerted through its cytokine and immunomodulatory activity and its regulatory effect on the activation and nuclear translocation of transcription factors in B16F-10 melanoma cells

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 1, 2008, Pages 49-63

  Guruvayoorappan, Chandrasekharan ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Activated transcription factor; Biophytum sensitivum; Cytokines; Hydroxyproline; Metastasis; Nuclear factor B

Indexed keywords

BIOPHYTUM SENSITIVUM EXTRACT; COLLAGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXOSAMINE; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PLANT EXTRACT; PROTEIN C FOS; PROTEIN P50; SIALIC ACID; SYNAPTOTAGMIN I; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URONIC ACID; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG METASTASIS; MALE; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANGIOSPERMS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PHYTOTHERAPY; PLANT EXTRACTS; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42149120728     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasm, origin and implications. Science 217: 998-1001, 1982.
2. Schirmacher V. Experimental approaches, theoretical concepts and impacts for treatment strategies. Adv Cancer Res 43:1-32, 1985.
3. Sugarman BEV, Ketchem AS. Mechanisms and presentation of cancer dissemination. An overview. Semin Oncol 19-32, 1977.
4. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol 62: S3-S10, 1992.
5. Lazar-Moinar E, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12: 547-554, 2000.
6. Dong G, Chen Z, Kato T, Vas Waes C. The host environment promotes the constitutive activation of nuclear factor-kappa B and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59: 3495-3504, 1999.
7. Siebenlist U, Franzoso G, Brown K. Structure regulation and function of NF-κB. Ann Rev Cell Biol 10: 405-455, 1994.
8. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-κB: key elements of proinflammatory signaling. Semin Immunol 12: 85-98, 2000.
9. Silverman N, Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev 15: 2321-2342, 2001.
10. Bruce AC. Anticancer drugs. In V.T. Devitta, S. Hellman, S.A. Rosenberg (ed), Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott; 1993, p. 325-340.
11. Poste G. Pathogenesis of metastatic disease; implications for the development of new therapeutic strategies. Cancer Treat Rep 70: 1223-1227, 1986.
12. Pizzo PA. Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges. Cancer 54: 2649, 1984.
13. Leyon PV, Kuttan G. Inhibitory effect of a polysaccharide from Tinospora cordifolia on experimental metastasis. J Ethnopharmacol 90: 223-237, 2004.
14. Leyon PV, Lini CC, Kuttan G. Inhibitory effect of Boerhaavia diffusa on experimental metastasis by B16F10 melanoma in C57BL/6 mice. Life Sci 76: 1339-1349, 2005
15. Sunila ES, Kuttan G. A preliminary study on antimetastatic activity of Thuja occidentalis L. in mice model. Immunopharmacol Immunotoxicol 28: 269-280, 2006.
16. Jachak SM, Bucar F, Kartnig T. Anti-inflammatory activity of Biophytum sensitivum in carrageenin induced rat paw oedema. Phytother Res 13: 73-74, 1999.
17. Puri D. The insulinotropic activity of the Nepalese medicinal plant Biophytum sensitivum, preliminary experimental study. J Ethnopharmacol 78: 89-93, 2001.
18. Guruvayoorappan C, Afira AH, Kuttan G. Antioxidant potential of Biophytum sensitivum extract in vitro and in vivo. J Basic Clin Physiol Pharmacol 17: 255-267, 2006.
19. Guruvayoorappan C, Kuttan G. Immunomodulatory and antitumor activity of Biophytum sensitivum extract. Asian Pacific J Cancer Prev 8: 27-32, 2007.
20. Guruvayoorappan C, Kuttan G. Anti-angiogenic effect of Biophytum sensitivum is exerted through its cytokine modulation activity and inhibitory activity against VEGF mRNA expression, endothelial cell migration and capillary tube formation. J Exp Ther Oncol 6: 241-250, 2007.
21. Lin YL, Wang WY. Chemical constituents of Biophytum sensitivum. Clin Pharm J 55:71-75, 2003.
22. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using MTT assay. Cancer Chemother Pharmacol 17: 259-263, 1986.
23. Liotta LA. B16F-10 cells readily causes pulmonary metastasis after injection through tail vein. Cancer Res 46 (1986) 1-4.
24. Bergman I, Loxley R. The determination of hydroxyproline in urine hydrolysate. Clin Chim Acta 27: 347-349, 1970.
25. Bitter T, Mair AM. The determination of hydroxyproline in urine hydrolysate. Clin Chim Acta 62: 330-334, 1962.
26. Schiller S, Solver A, Dartman A. A method for the separation of mucopolysaccharides, its application to the isolation of heparin from the skin of rat. J Biol Chem 236: 983-987, 1991.
27. Elson LA, Morgan WTJ. A colorimetric method for the determination of glucosamine and chondrasamine. J Biochem 27: 1824-1828, 1993.
28. Burton MP. Glucosamine 6 phosphate from glutamine. In Colowick SP, Kaplan NO(ed): Methods in Enzymology. New York: Academic Press; 1962. p 408-409.
29. Bhavanandhan VP, Kallic AW, Banks J, et al. Partial characterization of sialoglucopeptides produced by cultured human melanoma cells and melanocytes. Biochemistry 20: 3586-3594, 1981.
30. Tate SS, Meister A. Inhibition of gamma glutamyl transpeptidase aminoacids, peptides and derivatives and analogs of glutathione. J Biochem 23:1602, 1974.
31. Yoon TJ, Yoo YC, Kang TB, et al. Prophylactic effect of Korean mistletoe (Viscum album coloratum) extract on tumor metastasis is mediated by enhancement of NK cell activity. Int J Immunopharmacol 20:163-172, 1998.
32. Gupta SK, Bhattacharya B. Cytotoxicity assays. In A Handbook of Practical Immunology; Talwar GP(ed) Vikas Publishing House. New Delhi, 1983. p. 328-336.
33. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
34. Shen Z, Peedikayil J, Olson GK, Siebert PD, Fang Y. Multiple transcription factor profiling by enzyme-linked immunoassay. Bio Techniques 32: 1168-1177, 2002.
35. Nicolson GL, Fidler IJ. Tumour Progression & Metastasis: Alan R. Liss: New York; 1988.
36. Tarin D. Cancer metastasis. In Oxford Textbook of Oncology, Peckham M, Herbert M, Pinedo HM, Veronesi U(ed). Oxford University Press: Oxford, 1995, p. 118-132.
37. Fresa KL, Murasko DM. Role of natural killer cells in the mechanism of the antitumor effect of interferon on moloney sarcoma virus-transformed cells. Cancer Res 46: 81-88, 1986.
38. Voet D, Voet JG. Biochemistry. John Wiley, New York, 1995, p. 157-258.
39. Vedolva E, Borovansky J. Evaluation of serum sialic acid fractions as marker from malignant melanoma. Cancer Lett 78: 171-175, 1994.
40. Meister A. Selective modification of glutathione metabolism. Science 220: 472-477, 1983.
41. Andela VB, Schwarz EM, Puzas JE, O'Keefe J, Roiser RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by Nuclear factor-κB. Cancer Res 60: 6557-6562, 2000.
42. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor-κB p50/p65 and Fra-1 and Jun-D essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215, 2003.
43. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol 62: S3-S10, 1992.
44. Perussia B. The cytokine profile of resting and activated NK cells. Methods 9: 370-378, 1996.
45. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163: 4647-4650, 1999.
46. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumor growth and metastasis in beige mice. Nature 284: 622-624, 1980.
47. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850-861, 2002.
48. Prezioso JA, Wang N, Duty L, et al. Enhancement of pulmonary metastasis formation and gammaglutamyltranspeptidase activity in B16 melanoma induced by differentiation in vitro. Clin Exp Metastasis 11: 263-274, 1993.
49. Sinkovics JG, Harovath JC. Human natural killer cells: A comprehensive review. Int J Oncol 27: 5-47, 2005.
50. Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest 20: 1-14, 2002.
51. Del Rio M, De la Fuente M. Stimulation of natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities in murine leukocytes by bomesin-related peptides requires the presence of adherent cells. Regul Pept 60: 159-166, 1995.
52. Oliff A, Defeo-Jones D, Boyer M, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50: 555-563, 1987.
53. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167: 1211-1227, 1988.
54. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 8: 504-512, 1994.
55. Springer, TA. Traffic signals for lymphocyte recirculation and leukocyte migration: the multistep paradigm. Cell 76: 301-314, 1994.
56. Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest 86: 1945-1953, 1990.
57. Strieter RM, Phan SH, Showell HJ, et al. Monokine-induced neutrophil chemotactic factor gene expression in human fibroblasts. J Biol Chem 264: 10621-10626, 1989.
58. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 87: 2095-2147, 1986.
59. Song KS, Lee WJ, Chung KC, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem 278: 23243-23250, 2003.
60. Chen Z, Malhotra PS, Thoma GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379, 1999.
61. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355: 248-250, 2000.
62. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
63. Suzuki A, Takahashi T, Nakamura K, et al. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 80: 2052-2059, 1992.
64. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factors and angiogenesis. Pharmacol Rev 56: 549-580, 2004.
65. Woessner JF, Nagase N. Matrix metalloproteinases and TIMPs. First edn. New York: Oxford University Press, 2000.
66. McCawley LJ, Matrisian LM. Tumor progression: Defining the soil around the tumor seed. Curr Biol 11: R25-R27, 2001.
67. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. The matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
68. Chambers AF, Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
69. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 102: 39-44, 2002.
70. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation, and biological functions. Eur J Cell Biol 74: 111, 1997.
71. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252, 2002.
72. Siebenlist U, Franzoso G, Brown K. Structure regulation and function of NF-κB. Annu Rev Cell Biol 10: 405-455, 1994.
73. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947, 1999.
74. Sharma HW, Narayanan T. The NF-kappa B transcription factor in oncogenesis. Anticancer Res 16: 589-596, 1996.
75. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κB is unregulated in coleorectal cancer. Surgery 130: 363-369, 2001.
76. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-κB during progression of breast cancer to hormone independent growth. Mol Cell Biol 17: 3629-3639, 1997.
77. Mori N, Fujii M, Ikada S, et al. Constitutive action of NF-κB in primary adult T-cell leukemia cells. Blood 93: 2360-2368, 1999.
78. Neurath MF, Becker C, Barbulescu K. Role of NF-κB in immune and inflammatory response in the gut. Gut 439: 858-860, 1998.
79. Sun SC, Xiao G. Deregulation of NF-κB and its upstream kinases in cancer. Cancer Metastasis Rev 22: 405-422, 2003.
80. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
81. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20: 2413-2423, 2001.
82. Shaulian E, Karin M. AP-1 as regulator of cell life and death. Nat Cell Biol 4: E131-E136, 2002.
83. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 6: 391-411, 1996.
84. Wastermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
85. Huang C, Huang Y, Lee J et al. Inhibition of benzopyrene diol epoxide-induced transactivation of activated protein-1 and nuclear factor-κ B by black raspberry extracts. Cancer Res 63: 2206-2215, 2003.
86. Huang C, Chen N, Ma WY, Dong Z. Vanadium induce AP-1 and NF-κB dependent transcription activity. Int J Oncol 13: 711-715, 1998.
87. Angel P, Karin M. The role of Jun, Fos and the AP-complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
88. Zhong H, Voll R, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1: 29411-29416, 1999.